DE19632423A1 - Thienopyrimidine - Google Patents

Thienopyrimidine

Info

Publication number
DE19632423A1
DE19632423A1 DE19632423A DE19632423A DE19632423A1 DE 19632423 A1 DE19632423 A1 DE 19632423A1 DE 19632423 A DE19632423 A DE 19632423A DE 19632423 A DE19632423 A DE 19632423A DE 19632423 A1 DE19632423 A1 DE 19632423A1
Authority
DE
Germany
Prior art keywords
pyrimidine
chloro
pyridin
thieno
methylthieno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19632423A
Other languages
German (de)
English (en)
Inventor
Rochus Dr Jonas
Pierre Prof Dr Schelling
Franz-Werner Dr Kluxen
Maria Christadler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Priority to DE19632423A priority Critical patent/DE19632423A1/de
Priority to UA99031300A priority patent/UA55421C2/uk
Priority to JP50934398A priority patent/JP4405593B2/ja
Priority to PCT/EP1997/004139 priority patent/WO1998006722A1/de
Priority to AT97940047T priority patent/ATE233265T1/de
Priority to SI9730518T priority patent/SI0920431T1/xx
Priority to RU99104796/04A priority patent/RU2199541C2/ru
Priority to US09/230,806 priority patent/US6110920A/en
Priority to CN97197179A priority patent/CN1081638C/zh
Priority to PL97331538A priority patent/PL190174B1/pl
Priority to HU0001607A priority patent/HUP0001607A3/hu
Priority to HK00100583.3A priority patent/HK1021731B/xx
Priority to NZ334600A priority patent/NZ334600A/xx
Priority to CZ1999448A priority patent/CZ287772B6/cs
Priority to PT97940047T priority patent/PT920431E/pt
Priority to DK97940047T priority patent/DK0920431T3/da
Priority to AU42035/97A priority patent/AU725227B2/en
Priority to CA002263561A priority patent/CA2263561C/en
Priority to ES97940047T priority patent/ES2191192T3/es
Priority to KR10-1999-7001153A priority patent/KR100502271B1/ko
Priority to SK164-99A priority patent/SK282823B6/sk
Priority to IL12850497A priority patent/IL128504A/xx
Priority to TR1999/00308T priority patent/TR199900308T2/xx
Priority to DE59709404T priority patent/DE59709404D1/de
Priority to BR9711062A priority patent/BR9711062A/pt
Priority to EP97940047A priority patent/EP0920431B1/de
Priority to TW086111481A priority patent/TW359672B/zh
Priority to ZA9707156A priority patent/ZA977156B/xx
Priority to ARP970103649A priority patent/AR009052A1/es
Publication of DE19632423A1 publication Critical patent/DE19632423A1/de
Priority to NO990643A priority patent/NO990643L/no
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE19632423A 1996-08-12 1996-08-12 Thienopyrimidine Withdrawn DE19632423A1 (de)

Priority Applications (30)

Application Number Priority Date Filing Date Title
DE19632423A DE19632423A1 (de) 1996-08-12 1996-08-12 Thienopyrimidine
AU42035/97A AU725227B2 (en) 1996-08-12 1997-07-30 Thienopyrimidines
DK97940047T DK0920431T3 (da) 1996-08-12 1997-07-30 Thienopyrimidiner.
PCT/EP1997/004139 WO1998006722A1 (de) 1996-08-12 1997-07-30 Thienopyrimidine
AT97940047T ATE233265T1 (de) 1996-08-12 1997-07-30 Thienopyrimidine
SI9730518T SI0920431T1 (en) 1996-08-12 1997-07-30 Thienopyrimidines
RU99104796/04A RU2199541C2 (ru) 1996-08-12 1997-07-30 Тиенопиримидины, способ их получения (варианты), фармацевтическая композиция и способ ее получения
US09/230,806 US6110920A (en) 1996-08-12 1997-07-30 Thienopyrimidines
CN97197179A CN1081638C (zh) 1996-08-12 1997-07-30 噻吩并嘧啶化合物
PL97331538A PL190174B1 (pl) 1996-08-12 1997-07-30 Nowe związki, tienopirymidyny, sposób ich wytwarzania oraz preparat farmaceutyczny
HU0001607A HUP0001607A3 (en) 1996-08-12 1997-07-30 Thienopyrimidine derivatives, pharmaceutical compositions containing them, process for their preparation and use of the compounds
HK00100583.3A HK1021731B (en) 1996-08-12 1997-07-30 Thienopyrimidines
NZ334600A NZ334600A (en) 1996-08-12 1997-07-30 Thienopyrimidines inhibiting phosphodiesterase V for treating cardiovascular disease and impotency
CZ1999448A CZ287772B6 (en) 1996-08-12 1997-07-30 Thienopyrimidine derivative, process of its preparation and pharmaceutical preparation in which it is comprised
PT97940047T PT920431E (pt) 1996-08-12 1997-07-30 Tienopirimidinas
UA99031300A UA55421C2 (uk) 1996-08-12 1997-07-30 Тієнопіримідини, спосіб їх одержання (варіанти), фармацевтична композиція та спосіб її одержання
KR10-1999-7001153A KR100502271B1 (ko) 1996-08-12 1997-07-30 티에노피리미딘
JP50934398A JP4405593B2 (ja) 1996-08-12 1997-07-30 チエノピリミジン類
ES97940047T ES2191192T3 (es) 1996-08-12 1997-07-30 Tienopirimidinas.
CA002263561A CA2263561C (en) 1996-08-12 1997-07-30 Thienopyrimidines
SK164-99A SK282823B6 (sk) 1996-08-12 1997-07-30 Derivát tienopyrimidínu, spôsob jeho prípravy a farmaceutický prostriedok, ktorý ho obsahuje
IL12850497A IL128504A (en) 1996-08-12 1997-07-30 2-HETEROARYL-N-PHENYL (ALKYL) THIENO [2,3-d] PYRIMIDIN-4-AMINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
TR1999/00308T TR199900308T2 (xx) 1996-08-12 1997-07-30 Tiyenopirimidinler
DE59709404T DE59709404D1 (en) 1996-08-12 1997-07-30 Thienopyrimidine
BR9711062A BR9711062A (pt) 1996-08-12 1997-07-30 Tienopirimidinas
EP97940047A EP0920431B1 (de) 1996-08-12 1997-07-30 Thienopyrimidine
TW086111481A TW359672B (en) 1996-08-12 1997-08-11 Thienopyrimidines ad phosphodiesterase V antagonists, process for the production thereof and pharmaceutical compositions containing the same
ZA9707156A ZA977156B (en) 1996-08-12 1997-08-11 Thienopyrimidines.
ARP970103649A AR009052A1 (es) 1996-08-12 1997-08-12 Tienopirimidinas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen y un procedimiento para obtener estas preparaciones farmaceuticas
NO990643A NO990643L (no) 1996-08-12 1999-02-11 Tienopyrimidiner

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19632423A DE19632423A1 (de) 1996-08-12 1996-08-12 Thienopyrimidine

Publications (1)

Publication Number Publication Date
DE19632423A1 true DE19632423A1 (de) 1998-02-19

Family

ID=7802392

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19632423A Withdrawn DE19632423A1 (de) 1996-08-12 1996-08-12 Thienopyrimidine
DE59709404T Expired - Lifetime DE59709404D1 (en) 1996-08-12 1997-07-30 Thienopyrimidine

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE59709404T Expired - Lifetime DE59709404D1 (en) 1996-08-12 1997-07-30 Thienopyrimidine

Country Status (28)

Country Link
US (1) US6110920A (OSRAM)
EP (1) EP0920431B1 (OSRAM)
JP (1) JP4405593B2 (OSRAM)
KR (1) KR100502271B1 (OSRAM)
CN (1) CN1081638C (OSRAM)
AR (1) AR009052A1 (OSRAM)
AT (1) ATE233265T1 (OSRAM)
AU (1) AU725227B2 (OSRAM)
BR (1) BR9711062A (OSRAM)
CA (1) CA2263561C (OSRAM)
CZ (1) CZ287772B6 (OSRAM)
DE (2) DE19632423A1 (OSRAM)
DK (1) DK0920431T3 (OSRAM)
ES (1) ES2191192T3 (OSRAM)
HU (1) HUP0001607A3 (OSRAM)
IL (1) IL128504A (OSRAM)
NO (1) NO990643L (OSRAM)
NZ (1) NZ334600A (OSRAM)
PL (1) PL190174B1 (OSRAM)
PT (1) PT920431E (OSRAM)
RU (1) RU2199541C2 (OSRAM)
SI (1) SI0920431T1 (OSRAM)
SK (1) SK282823B6 (OSRAM)
TR (1) TR199900308T2 (OSRAM)
TW (1) TW359672B (OSRAM)
UA (1) UA55421C2 (OSRAM)
WO (1) WO1998006722A1 (OSRAM)
ZA (1) ZA977156B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2261863C2 (ru) * 2000-06-29 2005-10-10 Мерк Патент Гмбх 2-аминоалкилтиено[2,3-d]пиримидины, способ их получения, лекарственный препарат и способ его получения

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19819023A1 (de) * 1998-04-29 1999-11-04 Merck Patent Gmbh Thienopyrimidine
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
EP1167367A4 (en) 1999-03-30 2002-04-24 Nippon Soda Co THIENOPYRIMIDINE COMPOUNDS AND SALTS THEREOF, AND PROCESS FOR THE PREPARATION THEREOF
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
DE19950647A1 (de) * 1999-10-21 2001-04-26 Merck Patent Gmbh Imidazolderivate als Phosphodiesterase VII-Hemmer
AU2001290311A1 (en) * 2000-09-29 2002-04-08 Nippon Soda Co., Ltd. Thienopyrimidine compounds and their salts and process for preparation of both
WO2002062343A2 (en) * 2001-02-02 2002-08-15 Merck Patent Gmbh PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
CN101100472A (zh) * 2001-04-30 2008-01-09 美国拜尔公司 4-氨基-5,6-取代的噻吩并[2,3-d]嘧啶化合物及其应用
CN1261437C (zh) * 2001-09-04 2006-06-28 阿克佐诺贝尔公司 具有LH与FSH联合激动活性的甘氨酸-取代的噻吩并[2,3-d]嘧啶
WO2003035653A1 (en) * 2001-10-26 2003-05-01 Nippon Soda Co.,Ltd. Pyridothienopyrimidine compound and salt thereof
US7153412B2 (en) 2001-12-28 2006-12-26 Kabushiki Kaisha Toyota Chuo Kenkyusho Electrodes, electrochemical elements, gas sensors, and gas measurement methods
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
AR044743A1 (es) * 2002-09-26 2005-10-05 Nihon Nohyaku Co Ltd Herbicida, metodo de emplearlo, derivados de tienopirimidina sustituida,compuestos intermediarios, y procedimientos que se utilizan para producirlos,
GB0320300D0 (en) * 2003-08-29 2003-10-01 Cancer Rec Tech Ltd Pyrimidothiophene compounds
DE10351436A1 (de) * 2003-11-04 2005-06-09 Merck Patent Gmbh Verwendung von Thienopyrimidinen
GB0420719D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
TWI417095B (zh) * 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) * 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
TWI445532B (zh) 2007-09-14 2014-07-21 Janssen Pharmaceuticals Inc 1’,3’-二取代-4-苯基-3,4,5,6-四氫-2h,1’h-〔1,4’〕聯吡啶基-2’-酮化物
AU2008297877C1 (en) * 2007-09-14 2013-11-07 Addex Pharma S.A. 1,3-disubstituted-4-phenyl-1 H-pyridin-2-ones
CN101848893B (zh) 2007-09-14 2012-06-06 奥梅-杨森制药有限公司 1,3-二取代的4-(芳基-x-苯基)-1h-吡啶-2-酮
CA2704436C (en) * 2007-11-14 2016-01-05 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US20100227853A1 (en) * 2008-04-18 2010-09-09 Trustees Of Boston College Inhibitors of cyclic amp phosphodiesterases
KR101523126B1 (ko) 2008-07-31 2015-05-26 세노믹스, 인코포레이티드 단맛 향상제의 제조 방법 및 중간체
ES2439291T3 (es) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
CN102186477B (zh) 2008-10-16 2013-07-17 奥梅-杨森制药有限公司 作为代谢型谷氨酸受体调节剂的吲哚和苯并吗啉衍生物
CA2744138C (en) 2008-11-28 2015-08-11 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
SI2430022T1 (sl) 2009-05-12 2014-04-30 Janssen Pharmaceuticals, Inc. 1,2,3-triazolo(4,3-a)piridin derivati in njihova uporaba za zdravljenje ali prepreäśevanje nevroloĺ kih in psihiatriäśnih nepravilnosti
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
BRPI1010831A2 (pt) 2009-05-12 2016-04-05 Addex Pharmaceuticals Sa derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
WO2012062751A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
ES2552455T3 (es) 2010-11-08 2015-11-30 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
WO2012062759A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
HK1198475A1 (en) 2011-07-19 2015-05-08 无限药品股份有限公司 Heterocyclic compounds and uses thereof
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
KR20150041040A (ko) 2012-08-06 2015-04-15 세노믹스, 인코포레이티드 단맛 향미 개질제
JO3155B1 (ar) 2013-02-19 2017-09-20 Senomyx Inc معدِّل نكهة حلوة
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
KR20220051273A (ko) 2014-01-21 2022-04-26 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
IL279202B2 (en) 2014-01-21 2023-09-01 Janssen Pharmaceutica Nv Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic subtype 2 receptor and their use
US10300042B2 (en) 2014-06-23 2019-05-28 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
CN109311868B (zh) 2015-12-22 2022-04-01 尚医治疗有限责任公司 用于治疗癌症和炎性疾病的化合物
BR112019027640A2 (pt) 2017-06-21 2020-07-07 SHY Therapeutics LLC composto, método para testar a capacidade de um ou mais compostos, método para inibir a função de ras, método para inibir a função de rho, método para inibir a função de rac, composição farmacêutica
BR112021002261A2 (pt) 2018-08-07 2021-05-04 Firmenich Incorporated 2,2-dióxidos de 4-amino-1h-benzo[c][1,2,6]tiadiazina 5-substituídos e formulações e usos dos mesmos
US12391705B2 (en) 2018-12-19 2025-08-19 Shy Therapeutics, Llc Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
CN116178374B (zh) * 2023-01-13 2024-10-08 河北医科大学 小电导钙激活钾离子通道激动剂及其合成和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1570494A (en) * 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
US4196207A (en) * 1977-05-23 1980-04-01 Ici Australia Limited Process for controlling eradicating or preventing infestations of animals by Ixodid ticks
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 4−アミノキナゾリン誘導体およびそれを含有する医薬品
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5869486A (en) * 1995-02-24 1999-02-09 Ono Pharmaceutical Co., Ltd. Fused pyrimidines and pyriazines as pharmaceutical compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2261863C2 (ru) * 2000-06-29 2005-10-10 Мерк Патент Гмбх 2-аминоалкилтиено[2,3-d]пиримидины, способ их получения, лекарственный препарат и способ его получения

Also Published As

Publication number Publication date
NO990643D0 (no) 1999-02-11
SK16499A3 (en) 1999-06-11
JP2000516223A (ja) 2000-12-05
EP0920431B1 (de) 2003-02-26
IL128504A (en) 2003-01-12
DE59709404D1 (en) 2003-04-03
BR9711062A (pt) 1999-08-17
UA55421C2 (uk) 2003-04-15
JP4405593B2 (ja) 2010-01-27
AR009052A1 (es) 2000-03-08
AU4203597A (en) 1998-03-06
CN1227560A (zh) 1999-09-01
HUP0001607A2 (hu) 2000-10-28
TR199900308T2 (xx) 1999-04-21
AU725227B2 (en) 2000-10-12
DK0920431T3 (da) 2003-06-02
ES2191192T3 (es) 2003-09-01
SK282823B6 (sk) 2002-12-03
HUP0001607A3 (en) 2002-09-30
SI0920431T1 (en) 2003-08-31
CN1081638C (zh) 2002-03-27
NZ334600A (en) 2000-07-28
PL331538A1 (en) 1999-07-19
HK1021731A1 (en) 2000-06-30
CZ44899A3 (cs) 1999-05-12
CA2263561A1 (en) 1998-02-19
IL128504A0 (en) 2000-01-31
CZ287772B6 (en) 2001-01-17
WO1998006722A1 (de) 1998-02-19
RU2199541C2 (ru) 2003-02-27
US6110920A (en) 2000-08-29
ZA977156B (en) 1998-02-19
KR100502271B1 (ko) 2005-07-22
NO990643L (no) 1999-02-11
PL190174B1 (pl) 2005-11-30
ATE233265T1 (de) 2003-03-15
EP0920431A1 (de) 1999-06-09
CA2263561C (en) 2007-02-20
KR20000029932A (ko) 2000-05-25
TW359672B (en) 1999-06-01
PT920431E (pt) 2003-07-31

Similar Documents

Publication Publication Date Title
DE19632423A1 (de) Thienopyrimidine
WO1998017668A1 (de) Thienopyrimidine mit pde v inhibierender wirkung
EP1036078B1 (de) Thienopyrimidine
EP1337256A2 (de) Verwendung von thienopyrimidinen
EP1210349B1 (de) Pyrazolo[4, 3-d]pyrimidine
EP1084125B1 (de) Kondensierte thienopyrimidine mit pde v inhibierender wirkung
DE19928146A1 (de) Thienopyrimidine
DE10064994A1 (de) Sulfamidothienopyrimidine
EP1355649A2 (de) Pharmazeutische formulierung enthaltend pyrazolo 4,3-d]pyrimidine und nitrate oder thienopyrimidine und nitrate
DE10058662A1 (de) Verwendung von Pyrazolo[4,3-d]pyrimidinen
EP1294729B1 (de) 2-aminoalkyl-thieno[2,3-d]pyrimidine
EP1351962B1 (de) Thienopyrimidine
DE19944604A1 (de) Aminderivate
DE19943815A1 (de) Verwendung von Thienopyrimidinen
MXPA99001387A (en) Thienopyrimidines
DE10104096A1 (de) Pharmazeutische Formulierung enthaltend Thienopyrimidine und Nitrate
DE10104801A1 (de) Pharmazeutische Formulierungen enthaltend Thienopirimidine und Endothelin-Rezeptor-Antagonisten (2)

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee